Search Results
Found 1 results
510(k) Data Aggregation
(89 days)
Novapak Nasal Sinus Packing and Stent
The Novapak Nasal Sinus Packing and Stent is intended for use in patients undergoing nasal/sinus surgery as a space occupying packing to:
- · Separate tissue or structures compromised by surgical trauma.
- · Separate and prevent adhesions between mucosal surfaces in the nasal cavity.
- · Control minimal bleeding following surgery or trauma by tamponade effect, blood absorption, and platelet aggregation.
- · Act as an adjunct to aid in the natural healing process.
Novapak is indicated for use as a nasal packing to treat epistaxis.
Novapak™ is a single use, nasal packing and stent for use following sinus surgery to prevent adhesions, control mild bleeding and provide a level of antibacterial effectiveness. Novapak™ is composed of formulated chitosan and cellulose ingredients in a sponge can be compressed for insertion into anatomy and can be cut to size.
Novapak™ hydrates with sterile saline and forms a gel. The sponge dissolves within the nasal cavity with daily irrigation and natural mucus flow over several days. Residence time is typically 7-14 days with adequate irrigation. Alternately, the dressing may be removed through gentle aspiration at the discretion of the physician.
This FDA 510(k) summary describes the Novapak™ Nasal Sinus Packing and Stent and its substantial equivalence to a predicate device. The information provided heavily focuses on the physical and biological performance of the device rather than a clinical study with human readers or AI performance. Therefore, many of the requested categories related to AI performance, multi-reader studies, and expert ground truth cannot be answered from this document.
Here's an analysis of the provided text in relation to your request:
1. Table of acceptance criteria and the reported device performance
Acceptance Criteria Category | Acceptance Criteria (Implicit from "All samples passed testing and met the acceptance criteria of the specification.") | Reported Device Performance |
---|---|---|
Material Properties | - Absorption and hydration (saline and blood) | All samples passed |
- Degradation | All samples passed | |
- Compression | All samples passed | |
Biocompatibility | - Compliance with ISO 10993 and FDA guidance | Complies |
Sterilization | - Minimum sterility assurance level (SAL) of 10-6 | Validated to deliver SAL of 10-6 |
Hemostasis | - Hemolysis | All samples passed |
- Platelet activation | All samples passed | |
Antibacterial | - Bacterial Log Reduction Testing against specified strains | Demonstrated antibacterial activity for various timeframes (24 hours, 48 hours, 3 days, 7 days) against listed pathogens. |
- Bacterial Barrier Testing | Acts as a protective barrier for 72 hours, preventing bacterial growth through the hydrated sponge. | |
Shelf Life | - Packaging integrity (after transportation, high altitude, environmental conditioning) | All samples passed |
- Product real-time aging stability | All samples passed |
2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
The document does not specify exact sample sizes for each test ("all samples passed testing"). The data provenance is not explicitly stated in terms of country of origin or whether it was retrospective/prospective, but all testing was conducted on the device itself (sterile final product) and its packaging in a laboratory setting. This is therefore prospective laboratory testing.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
Not applicable. This device is a physical medical device (nasal packing and stent), not a diagnostic AI system requiring expert interpretation or ground truth establishment in a clinical sense. The "ground truth" for its performance is derived from laboratory tests and established standards.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable. This is not a study involving human reader interpretation or clinical adjudication.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This submission concerns a physical medical device, not an AI-assisted diagnostic tool.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Not applicable. This is not an algorithm or AI device.
7. The type of ground truth used (expert concensus, pathology, outcomes data, etc)
The "ground truth" for the device's performance is established through internationally recognized standards (e.g., ISO 10993 for biocompatibility) and laboratory tests. For example:
- Biocompatibility: Adherence to ISO 10993 guidelines.
- Sterilization: Meeting a validated sterility assurance level of 10-6.
- Absorption, degradation, compression, hemolysis, platelet activation, bacterial log reduction, bacterial barrier: Measured outcomes against internal specifications and relevant test methods.
- Shelf life and packaging integrity: Measured outcomes against internal specifications and relevant test methods, potentially following ASTM or other packaging standards.
8. The sample size for the training set
Not applicable. This is not an AI/ML device, so there is no "training set."
9. How the ground truth for the training set was established
Not applicable. There is no training set for a physical device like this.
Ask a specific question about this device
Page 1 of 1